These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment of depression by altering monoamine metabolism: precursors and metabolic inhibitors. Baldessarini RJ Psychopharmacol Bull; 1984; 20(2):224-39. PubMed ID: 6728992 [No Abstract] [Full Text] [Related]
5. Theoretical and therapeutic potential of indoleamine precursors. (5). Wirz-Justice A Nihon Rinsho; 1977 Apr; 35(4):1755-62. PubMed ID: 328960 [No Abstract] [Full Text] [Related]
6. [Interaction of L-DOPA and pyridoxine (a review of the literature)]. Uspenskiĭ AE Farmakol Toksikol; 1977; 40(6):722-33. PubMed ID: 340258 [No Abstract] [Full Text] [Related]
7. [Effect of levodopa on the arterial pressure and the metabolism of catecholamines in essential hypertension]. Zaldívar HM; Monroy JR; Sánchez Torres G; Chávez Lara B; Serrano PA Arch Inst Cardiol Mex; 1977; 47(5):591-603. PubMed ID: 603291 [No Abstract] [Full Text] [Related]
8. Tricyclic antidepressants and depletion of brain catecholamines. Preclinical and clinical studies with L-DOPA [proceedings]. Kabes J; Pöschlová N; Krsiak M; Dostal T; Masek K; Volsan O Act Nerv Super (Praha); 1976; 18(3):242-3. PubMed ID: 1007873 [No Abstract] [Full Text] [Related]
9. The psychiatrist attitudes and therapeutic means when faced with resistant depressions. Ginestet D Pharmakopsychiatr Neuropsychopharmakol; 1974 Jul; 7(4):194-8. PubMed ID: 4216905 [No Abstract] [Full Text] [Related]
10. Treating parkinsonism in the era of levodopa. McFarland HR Am Fam Physician; 1975 Sep; 12(3):99-104. PubMed ID: 240264 [No Abstract] [Full Text] [Related]
11. [Preclinical conception and clinical uses of L-dopa in combination with tricyclic antidepressives in pharmacoresistant depressions (author's transl)]. Kabes J; Pöschlová N; Krsiak M; Dostal T; Masek K; Volsan O Cesk Psychiatr; 1976 Oct; 72(5):324-31. PubMed ID: 1000695 [No Abstract] [Full Text] [Related]
12. [Clinical and biochemical considerations on depressive states occuring during parkinsonian syndrome treated by L-Dopa]. Gisselmann A; Boudry C; Marin A; Ballivet J Encephale; 1976; 2(2):105-13. PubMed ID: 1278088 [TBL] [Abstract][Full Text] [Related]
14. New antidepressant drugs: a clinical perspective. Gelenberg AJ Psychopharmacol Bull; 1984; 20(2):291-4. PubMed ID: 6728993 [No Abstract] [Full Text] [Related]
15. Effects of catecholic tetrahydroisoquinolines on endogenous catecholamines. Collins MA; Hannigan JJ; Weiner C Curr Alcohol; 1979; 5():53-9. PubMed ID: 755639 [No Abstract] [Full Text] [Related]
16. [Therapeutic use of L-dopa]. Kuran W Wiad Lek; 1975 Sep; 28(17):1467-72. PubMed ID: 1099814 [No Abstract] [Full Text] [Related]
17. Theoretical and therapeutic potential of indoleamine precursors. (1). Introduction. Wirz-Justice A Nihon Rinsho; 1976 Sep; 34(9):2741-5. PubMed ID: 1086914 [No Abstract] [Full Text] [Related]
18. [Parkinsonism following addition of fluoxetine to treatment with neuroleptics or carbamazepine]. Jansen EN; Kölling P Ned Tijdschr Geneeskd; 1992 Apr; 136(15):755-6. PubMed ID: 1560870 [No Abstract] [Full Text] [Related]
19. [Mechanisms of local anesthetic-induced convulsions. The relation to brain catecholamines]. Yoshimura Y Hiroshima Daigaku Shigaku Zasshi; 1984 Dec; 16(2):260-75. PubMed ID: 6442925 [No Abstract] [Full Text] [Related]
20. [Effect of L-dopa on the catecholamine content and myocardial ultrastructure and contractility in heart surgery]. Zavodskaia IS; Zabrodin ON; Zaskal'ko NI; Kucherenko RP; Nikitina NI Vestn Khir Im I I Grek; 1978 Feb; 120(2):13-8. PubMed ID: 644770 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]